A novel approach to systematically implement the universal definition of myocardial infarction: Insights from the CHAMPION PLATFORM trial

Heart

Volumn 99, Issue 17, 2013, Pages 1282-1287

  Leonardi, Sergio ^a,b   Truffa, Adriano A M ^a   Neely, Megan L ^a   Tricoci, Pierluigi ^a   White, Harvey D ^c   Gibson, C Michael ^d   Wilson, Matthew ^a   Stone, Gregg W ^e   Harrington, Robert A ^f   Bhatt, Deepak L ^g   Mahaffey, Kenneth W ^a  

^a DUKE UNIVERSITY   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f STANFORD UNIVERSITY   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CANGRELOR; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; TROPONIN;

ADULT; ANGINA PECTORIS; ARTICLE; CODING AND CLASSIFICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; STABLE ANGINA PECTORIS; UNIVERSAL DEFINITION;

ACUTE CORONARY SYNDROME; ADENOSINE MONOPHOSPHATE; AGED; BIOLOGICAL MARKERS; CREATINE KINASE, MB FORM; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TROPONIN;

EID: 84881481285     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-303103     Document Type: Article

References (22)

1. Roe MT, Mahaffey KW, Kilaru R, et al. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J 2004;25:313-21. (Pubitemid 38295440)
2. Akkerhuis KM, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-6. (Pubitemid 34123427)
3. Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 1999;33:88-96. (Pubitemid 29064078)
4. Bonaca MP, Wiviott SD, Braunwald E, et al. American College of Cardiology/ American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation 2012;125:577-83.
5. Leonardi S, Thomas L, Neely ML, et al. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. J Am Coll Cardiol 2012;60:2296-304.
6. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: receptor suppression using integrilin therapy. N Engl J Med 1998;339:436-43.
7. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
8. Tricoci P, Peterson ED, Mulgund J, et al. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol 2006;98:1172-6. (Pubitemid 44739918)
9. Lopes RD, Peterson ED, Chen AY, et al. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC Cardiovasc Interv 2010;3:669-77.
10. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-41.
11. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-95. (Pubitemid 350123680)
12. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98.
13. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29.
14. Gartlehner G, Hansen RA, Nissman D, et al. Criteria for distinguishing effectiveness from efficacy trials in systematic reviews. Technical Review 12 (Prepared by the RTI-International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.) AHRQ Publication No. 06-0046. Rockville, MD: Agency for Healthcare Research and Quality, 2006.
15. Antman EM. Decision making with cardiac troponin tests. N Engl J Med 2002;346:2079-82. (Pubitemid 34680601)
16. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009;360:2165-75.
17. White H, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012;163:182-90.
18. NACB Writing Group. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007;53:2086-96.
19. Tricoci P, Leonardi S, White JA, et al. Re-elevation of troponin following percutaneous coronary interventions significantly predicts 1-year mortality in patients with high-risk non-ST-segment elevation acute coronary syndromes. Circulation 2011;124:A9150.
20. Novack V, Pencina M, Cohen DJ, et al. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med 2012;172:502-8.
21. Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J 2012;163:768-76.
22. Lim CC, van Gaal WJ, Testa L, et al. With the "universal definition," measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. J Am Coll Cardiol 2011;57:653-61.